|
Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance
|
12/15/14
|
Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance
|
PDF
|
|
Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018
|
11/28/14
|
Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018
|
PDF
|
|
Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris
|
11/25/14
|
Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris
|
PDF
|
|
Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program
|
11/20/14
|
Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program
|
PDF
|
|
Valeant Comments On Allergan Announcement
|
11/17/14
|
Valeant Comments On Allergan Announcement
|
PDF
|
|
Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey
|
11/13/14
|
Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey
|
PDF
|
|
Valeant Pharmaceuticals Sends Letter To Physician Customers
|
11/07/14
|
Valeant Pharmaceuticals Sends Letter To Physician Customers
|
PDF
|
|
Valeant And Pershing Square May Vote At Special Meeting
|
11/04/14
|
Valeant And Pershing Square May Vote At Special Meeting
|
PDF
|
|
Valeant Delivers Letter To Allergan Board
|
10/27/14
|
Valeant Delivers Letter To Allergan Board
|
PDF
|
|
Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results
|
10/20/14
|
Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results
|
PDF
|
|
Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October 20, 2014
|
10/15/14
|
Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October 20, 2014
|
PDF
|
|
Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA
|
09/30/14
|
Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA
|
PDF
|
|
Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38%
|
09/26/14
|
Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38%
|
PDF
|
|
Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals
|
09/25/14
|
Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals
|
PDF
|
|
Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO™ (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies
|
09/25/14
|
Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO™ (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies
|
PDF
|
|
Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director
|
09/24/14
|
Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director
|
PDF
|
|
Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017
|
09/15/14
|
Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017
|
PDF
|
|
Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester
|
09/08/14
|
Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester
|
PDF
|
|
Valeant Extends Offer To Acquire Allergan
|
08/15/14
|
Valeant Extends Offer To Acquire Allergan
|
PDF
|
|
Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino
|
08/11/14
|
Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino
|
PDF
|
|
Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders
|
08/06/14
|
Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders
|
PDF
|
|
Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit
|
08/01/14
|
Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit
|
PDF
|
|
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
|
07/31/14
|
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
|
PDF
|
|
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results (pdf version)
|
07/31/14
|
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results (pdf version)
|
pdf
|
|
Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements
|
07/24/14
|
Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements
|
PDF
|
|
Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements
|
07/21/14
|
Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements
|
PDF
|
|
Valeant Pharmaceuticals Files Investor Presentation
|
07/18/14
|
Valeant Pharmaceuticals Files Investor Presentation
|
PDF
|
|
Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure
|
07/17/14
|
Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure
|
PDF
|
|
Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan
|
07/14/14
|
Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan
|
PDF
|
|
Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma
|
07/10/14
|
Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma
|
PDF
|
|
Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology
|
07/08/14
|
Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology
|
PDF
|
|
Valeant Files Preliminary Proxy Statement for Special Meeting of Shareholders to Approve Share Issuance in Proposed Acquisition of Allergan
|
06/25/14
|
Valeant Files Preliminary Proxy Statement for Special Meeting of Shareholders to Approve Share Issuance in Proposed Acquisition of Allergan
|
PDF
|
|
Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements
|
06/23/14
|
Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements
|
PDF
|
|
Valeant Commences Exchange Offer For Allergan
|
06/18/14
|
Valeant Commences Exchange Offer For Allergan
|
PDF
|
|
Valeant Pharmaceuticals Receives U.S. FDA Clearance For Restylane® Silk
|
06/16/14
|
Valeant Pharmaceuticals Receives U.S. FDA Clearance For Restylane® Silk
|
PDF
|
|
Valeant Pharmaceuticals Announces Planned Management Departure
|
06/13/14
|
Valeant Pharmaceuticals Announces Planned Management Departure
|
PDF
|
|
Valeant Pharmaceuticals To Hold Conference Call On Tuesday, June 17, 2014 To Correct Recent Misrepresentations
|
06/13/14
|
Valeant Pharmaceuticals To Hold Conference Call On Tuesday, June 17, 2014 To Correct Recent Misrepresentations
|
PDF
|
|
Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosis
|
06/09/14
|
Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosis
|
PDF
|
|
Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiations
|
05/30/14
|
Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiations
|
PDF
|
|
Valeant Substantially Increases Merger Proposal For Allergan
|
05/28/14
|
Valeant Substantially Increases Merger Proposal For Allergan
|
PDF
|
|
Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billion
|
05/28/14
|
Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billion
|
PDF
|
|
Valeant To Host In-Person Investor Meeting And Webcast On May 28, 2014 At 8:00 A.M. ET
|
05/27/14
|
Valeant To Host In-Person Investor Meeting And Webcast On May 28, 2014 At 8:00 A.M. ET
|
PDF
|
|
Valeant Pharmaceuticals to Present at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014
|
05/23/14
|
Valeant Pharmaceuticals to Present at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014
|
PDF
|
|
Valeant Pharmaceuticals Announces 2014 Annual Meeting Results
|
05/21/14
|
Valeant Pharmaceuticals Announces 2014 Annual Meeting Results
|
PDF
|
|
Valeant to Discuss Allergan Proposal at Investor Meeting and Webcast on May 28, 2014 at 8:00 A.M. ET
|
05/20/14
|
Valeant to Discuss Allergan Proposal at Investor Meeting and Webcast on May 28, 2014 at 8:00 A.M. ET
|
PDF
|
|
Valeant Pharmaceuticals Responds to Allergan's Rejection of Merger Proposal
|
05/13/14
|
Valeant Pharmaceuticals Responds to Allergan's Rejection of Merger Proposal
|
PDF
|
|
Valeant Pharmaceuticals Enters Into Patent Settlement Agreements With Actavis
|
05/12/14
|
Valeant Pharmaceuticals Enters Into Patent Settlement Agreements With Actavis
|
PDF
|
|
Valeant Pharmaceuticals Reports First Quarter 2014 Financial Results
|
05/08/14
|
Valeant Pharmaceuticals Reports First Quarter 2014 Financial Results
|
PDF
|
|
Valeant Pharmaceuticals To Webcast 2014 Annual Meeting Of Shareholders
|
05/01/14
|
Valeant Pharmaceuticals To Webcast 2014 Annual Meeting Of Shareholders
|
PDF
|
|
Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available
|
04/24/14
|
Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available
|
PDF
|
|
Valeant Pharmaceuticals To Announce 2014 First Quarter Results On May 8, 2014
|
04/24/14
|
Valeant Pharmaceuticals To Announce 2014 First Quarter Results On May 8, 2014
|
PDF
|
|
Valeant Pharmaceuticals Announces Nominations For Board Of Directors
|
04/23/14
|
Valeant Pharmaceuticals Announces Nominations For Board Of Directors
|
PDF
|
|
Valeant Proposes to Combine With Allergan for $48.30 in Cash and 0.83 Shares of Valeant Stock for Each Allergan Share
|
04/22/14
|
Valeant Proposes to Combine With Allergan for $48.30 in Cash and 0.83 Shares of Valeant Stock for Each Allergan Share
|
PDF
|
|
Actavis and Valeant Announce FDA Approval for Metronidazole 1.3%
|
03/25/14
|
Actavis and Valeant Announce FDA Approval for Metronidazole 1.3%
|
PDF
|
|
Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results
|
02/27/14
|
Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results
|
PDF
|
|
Valeant Pharmaceuticals To Announce 2013 Fourth Quarter And Full Year Results On February 27, 2014
|
02/05/14
|
Valeant Pharmaceuticals To Announce 2013 Fourth Quarter And Full Year Results On February 27, 2014
|
PDF
|
|
Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million
|
02/03/14
|
Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million
|
PDF
|
|
Valeant Pharmaceuticals Announces Approval of Retin-A Micro® Microsphere 0.08%
|
01/31/14
|
Valeant Pharmaceuticals Announces Approval of Retin-A Micro® Microsphere 0.08%
|
PDF
|
|
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Solta Medical, Inc.
|
01/23/14
|
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Solta Medical, Inc.
|
PDF
|
|
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Solta Medical, Inc.
|
01/23/14
|
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Solta Medical, Inc.
|
PDF
|
|
Valeant Pharmaceuticals Announces New $1.5 Billion Securities Repurchase Program
|
01/22/14
|
Valeant Pharmaceuticals Announces New $1.5 Billion Securities Repurchase Program
|
PDF
|
|
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
|
01/15/14
|
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
|
PDF
|
